26.02.2014 • News • BASF • Dede Willams • Dow

BASF Has No Plans to Revive Share Buyback Scheme

Unlike U.S. rivals such as Dow Chemical and DuPont, BASF has no plans to revive its share buyback program, the German group's CEO Kurt Bock told Reuters Inside TV.

Interviewed in conjunction with the annual results press conference in Ludwigshafen on Feb. 25, Bock said BASF would prefer to spend the money on new plant and equipment.

"We pay a handsome dividend and then the money is being spent, frankly," the news agency quotes Bock as saying. "We are rightly leveraged, there is little money left for buybacks." From 1999-2008, BASF purchased around €10 billion worth of its own stock.

Bock said also that the group would continue to focus on technology-driven, smaller acquisitions.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Top-Feature

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.